Podcast: This Week in Managed Care—CAR T Treatments and Other Health News

December 16, 2017

Article

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care^® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included coverage from the 59th American Society of Hematology Annual Meeting and Exposition; recommendations on the use of diabetes drugs with cardiovascular indications; and a new study found that despite changes in insurance plans to give consumers more clout, unnecessary medical spending remains a problem.

Listen below or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Read more about the stories in this podcast:

What We're Reading: Medical Device Approval; Medical Laboratories Sue Government; ACA Sign-Up Deadline

CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients

Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma

American Society of Hematology coverage

ADA 2018 Standards Address Drugs With CV Benefits, Hold Firm on Blood Pressure

Impact of Consumer-Directed Health Plans on Low-Value Healthcare

Recent Videos

Tami John, MD

Tami John, MD

Tami John, MD

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center

Related Content

Around the Helix: Cell and Gene Therapy Company Updates – July 2, 2025

Around the Helix: Cell and Gene Therapy Company Updates – July 2, 2025

Noah Stansfield

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.

Data Roundup: June 2025 Features Updates from EHA, ASCO, and More

Data Roundup: June 2025 Features Updates from EHA, ASCO, and More

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Tami John, MD

Considerations for β-Thalassemia Gene Therapy in the Real World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, discussed considerations for using beti-cel and exa-cel for TDT in the clinic.

Tami John, MD

Barriers to Access for Gene Therapy in β-Thalassemia

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, also provided background about the current state of care in TDT.

Related Content

Around the Helix: Cell and Gene Therapy Company Updates – July 2, 2025

Around the Helix: Cell and Gene Therapy Company Updates – July 2, 2025

Noah Stansfield

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.

Data Roundup: June 2025 Features Updates from EHA, ASCO, and More

Data Roundup: June 2025 Features Updates from EHA, ASCO, and More

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Tami John, MD

Considerations for β-Thalassemia Gene Therapy in the Real World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, discussed considerations for using beti-cel and exa-cel for TDT in the clinic.

Tami John, MD

Barriers to Access for Gene Therapy in β-Thalassemia

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, also provided background about the current state of care in TDT.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.